Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
复制标题
慢性非感染性关节炎的纳米医学：临床医生的观点。
DOI：
10.1016/j.nano.2012.05.004
复制
发表时间：
2012-09
影响因子：
5.4
通讯作者：
Weinberg, Guy L.
中科院分区：
文献类型：
--
作者：
Rubinstein, Israel;Weinberg, Guy L.
风湿性关节炎（RA）和骨关节炎（OA）是常见的慢性健康状况。然而，尽管最近在医学治疗方面取得了进展，但由于目前处方药物的安全性和有效性问题，它们的治疗仍然代表着未满足的医疗需求。因此，迫切需要开发和测试用于RA和OA的新药，其选择性地靶向发炎的关节，从而减轻对健康组织的损伤。可以想象，生物相容性，可生物降解，疾病缓解抗风湿纳米药物（DMARN）可能代表一个有前途的治疗方法，类风湿关节炎和OA。为此，载药纳米载体的独特物理化学性质与发炎关节的病理生理学特征相结合，放大了DMARN的生物利用度和生物活性，并促进其选择性靶向发炎关节。这反过来又最大限度地减少了控制关节炎症所需的药物量，并避免了对健康组织的附带损害。因此，纳米医学可以在受影响关节的炎症过程的空间和时间上提供选择性控制。然而，将用于RA和OA的安全有效的DMARN推向市场是具有挑战性的，因为监管机构对纳米技术没有官方定义，并且纳米医学的规则和定义仍在开发中。虽然现有的毒理学试验可能足以用于大多数DMARN，但随着确定了用于人类的新型纳米材料产生的新毒性风险和不良健康影响，还需要进行额外的毒理学试验。因此，我们建议在临床试验开始之前，必须对RA和OA有前景的DMARN电极导线进行详细的临床前体内安全性评估，包括对一般人群的风险。
Rheumatoid arthritis (RA) and osteoarthritis (OA) are prevalent chronic health conditions. However, despite recent advances in medical therapeutics, their treatment still represents an unmet medical need because of safety and efficacy concerns with currently prescribed drugs. Accordingly, there is an urgent need to develop and test new drugs for RA and OA that selectively target inflamed joints thereby mitigating damage to healthy tissues. Conceivably, biocompatible, biodegradable, disease-modifying antirheumatic nanomedicines (DMARNs) could represent a promising therapeutic approach for RA and OA. To this end, the unique physicochemical properties of drug-loaded nanocarriers coupled with pathophysiological characteristics of inflamed joints amplify bioavailability and bioactivity of DMARNs and promote their selective targeting to inflamed joints. This, in turn, minimizes the amount of drug required to control articular inflammation and circumvents collateral damage to healthy tissues. Thus, nanomedicine could provide selective control both in space and time of the inflammatory process in affected joints. However, bringing safe and efficacious DMARNs for RA and OA to the marketplace is challenging because regulatory agencies have no official definition of nanotechnology, and rules and definitions for nanomedicines are still being developed. Although existing toxicology tests may be adequate for most DMARNs, as new toxicity risks and adverse health effects derived from novel nanomaterials with intended use in humans are identified, additional toxicology tests would be required. Hence, we propose that detailed pre-clinical in vivo safety assessment of promising DMARNs leads for RA and OA, including risks to the general population, must be conducted before clinical trials begin.
登录
查看更多内容
影响因子：
2.4
作者：
Perez, AT;Domenech, GH;Vogel, CL
通讯作者：
Vogel, CL
DOI：
10.1124/jpet.108.150276
发表时间：
2009-05-01
影响因子：
3.5
作者：
Ishihara, Tsutomu;Kubota, Tetsushi;Higaki, Megumu
通讯作者：
Higaki, Megumu
影响因子：
12.8
作者：
Chang, Christopher
通讯作者：
Chang, Christopher
影响因子：
7
作者：
Kraus, V. B.;Burnett, B.;Todman, M.
通讯作者：
Todman, M.
影响因子：
5.8
作者：
Brown, C. L.;Whitehouse, M. W.;Bushell, G. R.
通讯作者：
Bushell, G. R.